QHSLab (OTCQB:USAQ) Announces Launch of Q-Cog(TM) to Support Early Detection of Mild Cognitive Impairment and Dementia
MWN-AI** Summary
QHSLab Inc. (OTCQB: USAQ), a healthcare technology company focused on digital medicine and population health, announced the launch of Q-Cog™, a cloud-based cognitive assessment platform aimed at enhancing early detection of Mild Cognitive Impairment (MCI) and dementia in older adults. In an initial pilot study involving 168 patients aged 65 and over, 54% were identified as high-risk for cognitive impairment using Q-Cog™. This innovative tool combines various validated cognitive, behavioral, and functional assessments into a streamlined digital process, enabling primary care providers to adhere to CMS screening guidelines while improving risk adjustment and reimbursement capabilities.
Dr. Juan Oms, a psychiatrist and advisor to QHSLab, emphasized the importance of primary care clinicians in tackling cognitive decline, asserting that Q-Cog™ empowers them with a user-friendly tool for early identification. Despite guidelines encouraging screening, many cases of MCI and dementia remain undiagnosed due to time constraints and limited resources in routine medical visits. Q-Cog™ directly addresses this gap with a rapid, structured assessment process that allows for timely intervention.
Troy Grogan, the President and CEO of QHSLab, highlighted that early detection is critical and that Q-Cog™ offers a practical, reimbursable means for physicians to screen for cognitive decline during standard appointments. This development not only enhances patient care but also helps improve financial performance for value-based providers through better Risk Adjustment Factor (RAF) scoring.
Overall, the introduction of Q-Cog™ significantly advances QHSLab's digital medicine capabilities, catering to a pressing need in healthcare while creating potential new revenue streams for the company and its partners. Dr. Marcos Sánchez-González, the Vice President of Medical and Scientific Affairs, noted that Q-Cog™ integrates cognitive assessments with behavioral health, emphasizing the importance of holistic care strategies in effective prevention and treatment.
MWN-AI** Analysis
QHSLab Inc. (OTCQB: USAQ) has launched its innovative Q-Cog™ platform, a digital cognitive assessment tool designed for early detection of Mild Cognitive Impairment (MCI) and dementia. The pilot study revealed that 54% of participants aged 65 and older were identified as high-risk for cognitive decline, signifying a substantial unmet need in primary care that Q-Cog™ aims to address.
From a market perspective, this introduction positions QHSLab favorably amidst growing recognition of the importance of early detection in cognitive disorders – a crucial element for effective intervention and management that aligns with the CMS's Annual Wellness Visit requirements. The ability to enhance risk-adjusted reimbursement under existing neurocognitive and behavioral health codes can substantially benefit healthcare providers financially, thus driving adoption of Q-Cog™ throughout primary care settings.
For investors, QHSLab’s strategic positioning in value-based care could lead to increased revenue opportunities. The unique combination of cognitive, behavioral, and functional assessments in a single digital interface not only streamlines clinician workflows but also meets pressing demands for effective screening tools. As healthcare shifts towards preventative approaches, Q-Cog™ is well placed to capitalize on this trend.
However, potential investors should remain cautious of the inherent volatility in healthcare technology investments. The reliance on government programs for reimbursement and the need for widespread acceptance among primary care providers introduce elements of uncertainty that could affect QHSLab's market performance in the short term.
In conclusion, while the launch of Q-Cog™ offers promising growth potential, investors should analyze market conditions, competitive landscape, and regulatory environment closely. As QHSLab capitalizes on the increasing emphasis on early cognitive detection, this innovation could well position the company as a leader in digital health for cognitive assessments, potentially enhancing both clinical outcomes and financial returns.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Initial pilot of 168 patients aged 65 and older identifies 54% with high-risk cognitive scores; digital platform expands company’s value-based care capabilities.
West Palm Beach, FL, Dec. 03, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. (the “Company”) (OTCQB: USAQ), a healthcare technology company focused on digital medicine and population health innovation, today announced the introduction of Q-Cog ™ , a comprehensive, cloud-based cognitive assessment designed to help primary care providers identify Mild Cognitive Impairment (MCI) and dementia-related risks earlier in the disease process.
Q-Cog ™ combines validated cognitive, behavioral, and functional screening within a single digital workflow, empowering physicians to meet CMS screening guidelines while supporting risk adjustment and reimbursement under neurocognitive and behavioral health codes.
Juan Oms, MD, Psychiatrist and Medical Adviser
“Primary care clinicians are the first line of defense for cognitive decline,” said Dr. Juan Oms , Psychiatrist and Medical Adviser to QHSLab. “Q-Cog ™ equips them with a validated, patient-friendly digital tool to identify at-risk individuals and initiate early support before dementia becomes disabling.”
In an initial real-world pilot among 168 patients aged 65 and older, Q-Cog ™ identified 90 individuals (54%) at high risk for cognitive impairment and facilitated real-time telemedicine referrals—underscoring the significant unmet need for early detection in primary care. Despite national guidelines, more than 50% of Mild Cognitive Impairment cases and up to 60–80% of dementia cases go unrecognized during routine visits. This persistent diagnostic gap, driven by time pressures and limited tools, leaves many patients undetected until functional decline is apparent. Q-Cog ™ bridges this gap by delivering a fast, structured, digital assessment that enables primary-care clinicians to identify risk earlier and initiate timely, evidence-based follow-up.
Troy Grogan, President and CEO of QHSLab
“Early detection is where primary care can make the biggest impact,” said Troy Grogan , President and CEO of QHSLab. “Q-Cog ™ gives physicians a practical, reimbursable way to screen for cognitive decline during routine encounters, while also capturing data that supports value-based care and population-health performance.”
For investors, the launch of Q-Cog ™ represents a meaningful expansion of QHSLab’s reimbursable digital medicine platform. The solution aligns directly with CMS Annual Wellness Visit requirements, supports cognitive and behavioral health screening mandates, and generates documentation that qualifies for neurocognitive and behavioral health CPT codes. By identifying high-risk patients earlier, Q-Cog ™ also contributes to more accurate Risk Adjustment Factor (RAF) scoring for value-based providers—improving both care outcomes and financial performance. With few practical tools currently in widespread use at the primary-care level, Q-Cog ™ fills a critical gap in early dementia detection while opening new, scalable revenue opportunities for QHSLab and its provider partners.
Marcos Sánchez-González, MD, PhD, Vice President of Medical and Scientific Affairs
“Q-Cog ™ reflects our commitment to whole-person assessment,” said Dr. Marcos Sánchez-González , QHSLab’s Vice President of Medical and Scientific Affairs. “By integrating cognitive testing with behavioral health, daily function, and social determinants, we help clinicians understand not only the impairment but also the context — and that’s where prevention and effective care truly begin.”
About QHSLab
QHSLab, Inc. (OTCQB: USAQ) is a digital health technology leader providing preventive screening, assessment, and workflow solutions for primary care providers. Its tools help practices identify, document, and manage underdiagnosed chronic and behavioral conditions efficiently and profitably. Learn more at www.qhslab.com
Forward-Looking Statements
Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investor Relations Contact:
Olivia Giamanco
QHSLab, Inc.
(929) 379-6503
ir@usaqcorp.com
https://twitter.com/QHSLabInc
FAQ**
How does Q-Cog™ differentiate itself from existing cognitive assessment tools in the market, particularly in terms of efficacy and usability for primary care providers managing patients aged 65 and older, and what role does U S Alcohol Testing Amer Inc USAQ play in its development?
What specific strategies does QHSLab Inc. (USAQ) plan to implement to drive adoption of Q-Cog™ among primary care providers, and how does it align with current reimbursement policies and requirements from Medicare and CMS?
Given the initial pilot results showing 54% of participants at high cognitive risk, what mechanisms are in place for QHSLab Inc. (USAQ) to follow up on these patients, ensuring continuity of care and effective management of detected cognitive impairments?
Considering the projected expansion of Q-Cog™ as a scalable revenue opportunity, how does QHSLab Inc. (USAQ) plan to leverage the integration of cognitive and behavioral health assessments to enhance its value-based care initiatives and attract more provider partnerships?
**MWN-AI FAQ is based on asking OpenAI questions about U S Alcohol Testing Amer Inc (OTC: USAQ).
NASDAQ: USAQ
USAQ Trading
-1.33% G/L:
$0.7499 Last:
10,250 Volume:
$0.76 Open:
